Stock Researching
Incyte Corp. Surges on Trial Results
Stock Researching
Publish date: Wed, 21 Aug 2013, 11:15 AM
Stock Researching
0 241,468
Stockresearching is a blog designed to help the independent investor create new ideas and receive valuable informed information.
From Liston Street Pulse:
Shares of Incyte Corp. (INCY), a biopharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs, are rallying in trading today after the company announced top-line results from Phase II proof-of-concept trial of ruxolitinab in patients with refractory metastatic pancreatic cancer. INCY shares struck a 52-week […]
The post Incyte Corp. Surges on Trial Results appeared first on Liston Street Pulse.
More articles on Stock Researching
Enbridge Inc: 2016 Fundamental Analysis WACC, Cost of Debt and Cost of Equity $ENB
Created by Stock Researching | Dec 13, 2016
Apple Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $AAPL
Created by Stock Researching | Dec 04, 2016
Visa Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $V
Created by Stock Researching | Dec 02, 2016
Telus Corp. Cost of Debt, CAPM, WACC and Valuation $TU, $T.TO
Created by Stock Researching | Nov 19, 2016
Assessing Canadian Telecom Exposure, $BCE is worth a look
Created by Stock Researching | Nov 10, 2016
$UPS Deriving Value From E-Commerce Growth And Lower Energy Prices
Created by Stock Researching | Oct 05, 2015
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
3
CEO Morning Brief
4
CEO Morning Brief
Scaramucci Expects Bitcoin Record on Rate Cuts, Clearer US Rules
5
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
